![team_1919183396 [Converted].jpg](https://static.wixstatic.com/media/1199b8_df6274a736d04c429afa439528b8b7f0~mv2.jpg/v1/fill/w_84,h_49,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/1199b8_df6274a736d04c429afa439528b8b7f0~mv2.jpg)
Team
Unleashing the therapeutic potential of phytomedicine for a healthier world
MANAGEMENT TEAM
Jun Liu
CEO
-
30+ years of diverse encompassing pharmaceutical investment and research, hospital management, and real estate development, demonstrating versatility across industries
-
Demonstrated leadership in botanical and chemical drug research and development within the pharmaceutical sector, driving innovation and scientific breakthroughs
-
Former President of Duraviva Pharma Inc., where responsibilities included guiding the company's strategic direction and fostering growth through market expansion and product development
-
Bachelor's degree from Northeast Normal University
Huijuan Zhong, PhD
CSO
-
20+ years of experience in the pharmaceutical industry with expertise in drug substance and drug product development from preclinical through commercialization
-
Successful track record in one NDA submission (KarXT) and six ANDA/505(b)(2) NDA submissions, with four products on the market including Cobenfy, Buprenorphine products
-
Deep expertise in analytical method development, validation, transfer, specifications, and supporting clinical trials, registration, and PPQ
-
Extensive experience with analytical techniques including HPLC, GC, CE, IC, KF, particle size, FTIR, TGA/DSC, UV/vis, LC/QDa, fluorescence and dissolution
-
Successfully led 20+ analytical development projects and set up two GMP analytical labs
-
Postdoctoral research fellow at Northeastern University and Biogen, developing CE methods
-
PhD in Analytical Chemistry, University of York, UK
-
MSc in Environmental Analytical Chemistry and BSc in Organic Chemistry, Nanjing University, China
Liqin Xie, PhD
COO
-
15+ years of experience across big pharma (Regeneron) and startup biotech (Surrozen)
-
Led cross-functional teams to advance a first-in-class Ulcerative Colitis drug from discovery to IND
-
Deep expertise in drug discovery and development for multiple diseases and program leadership
-
Strong scientific acumen with 50+ publications and 5 patents
-
Postdoctoral fellow, inflammatory diseases, Georgia Institute of Technology
-
PhD, Biomedical Engineering, Stony Brook University
-
MD, Beijing University of Chinese Medicine
Ning Zhang, PhD
CTO
-
Professor and doctoral supervisor at Heilongjiang University of Traditional Chinese Medicine
-
Leads several key research centers focused on TCM quality control, health products, and cosmetics
-
Deep expertise in traditional Chinese medicine research, including active pharmaceutical ingredients, dosage forms, and pharmacokinetics
-
Prolific researcher with 300+ publications, including 41 SCI papers, 3 monographs, and 11 patents
-
Recipient of numerous provincial and national science and technology awards for TCM research
-
Postdoctoral fellow, Heilongjiang University of Traditional Chinese Medicine
-
PhD, Heilongjiang University of Traditional Chinese Medicine
-
MD, Shanghai Medical University
Wanjun (Victor) Zhang
CFO
-
25+ years of experience in finance and corporate management, including accounting, budgeting, financial analysis, internal controls, compliance, tax, and IPO preparation
-
Independent Financial Consultant since 2020, providing financial advisory services to companies across multiple industries
-
Former Finance Director at Perfect World (Beijing) Software Co., Ltd., a NASDAQ-listed company, overseeing BU budgeting, financial analysis, and subsidiary financial management
-
Extensive experience in pre-IPO readiness, SOX compliance, internal control systems, and audit coordination at both multinational and domestic companies
-
BA in Accounting from Central University of Finance and Economics, Beijing, China
BOARD OF DIRECTORS
Jun Liu
President
-
30+ years of diverse encompassing pharmaceutical investment and research, hospital management, and real estate development, demonstrating versatility across industries
-
Demonstrated leadership in botanical and chemical drug research and development within the pharmaceutical sector, driving innovation and scientific breakthroughs
-
Former President of Duraviva Pharma Inc., where responsibilities included guiding the company's strategic direction and fostering growth through market expansion and product development
-
Bachelor's degree from Northeast Normal University
Huijuan Zhong, PhD
Director
-
20+ years of experience in the pharmaceutical industry with expertise in drug substance and drug product development from preclinical through commercialization
-
Successful track record in one NDA submission (KarXT) and six ANDA/505(b)(2) NDA submissions, with four products on the market including Cobenfy, Buprenorphine products
-
Deep expertise in analytical method development, validation, transfer, specifications, and supporting clinical trials, registration, and PPQ
-
Extensive experience with analytical techniques including HPLC, GC, CE, IC, KF, particle size, FTIR, TGA/DSC, UV/vis, LC/QDa, fluorescence and dissolution
-
Successfully led 20+ analytical development projects and set up two GMP analytical labs
-
Postdoctoral research fellow at Northeastern University and Biogen, developing CE methods
-
PhD in Analytical Chemistry, University of York, UK
-
MSc in Environmental Analytical Chemistry and BSc in Organic Chemistry, Nanjing University, China
Helen Hsu, MD
Independent Director
Dr. Helen Hsu is a Medical Executive (M.D.) with 30 years of experience in drug discovery, clinical research and commercialization. Her leadership in Pharmaceutical /Biotech industry involves the whole life cycle management from preclinical R&D, translational research, to clinical program development, Medical Affairs and business development. Helen has spearheaded IND / NDA submissions and monitored global Phase I-V clinical trials in multiple therapeutic areas such as Oncology/Hematology, Neurology, Cardiology, GI, Women’s Health and Pediatric studies. Her broad experience spanning big pharma (GSK, Novartis, BI) to biotech (Epizyme, Ipsen) and CRO (Pharmaron), plus her skills in clinical practice and research program strategy are an asset for the Board.
During Helen’s tenure leading a the research department at a cancer center in the US, and building a research institute at the Harvard Medical School affiliated International Hospital in China, Helen successfully integrated the hospital research program and established a unique pathway for bringing innovative products to cancer patients.
Helen received her Medical Education from Southeast University Medical School followed by clinical practice as an Internist in China. She also completed her graduate studies at MSU and received her post-doctoral trainings in molecular biology and genetic disease from Albert Einstein College of Medicine and NYU Medical School Teaching Hospital in the US.
Yong Yan, PhD
Independent Director
-
20+ years of experience across leading financial firms including Credit Suisse, Merrill Lynch, PingAn Group, and Fosun Group
-
Co-founded BitDATA Exchange, a regulated digital asset trading platform, and led the development of Fosun's first internet-based alternative financial platform
-
Deep expertise in securitization, structured products, derivatives, fintech, blockchain and AI investments
-
Structured and designed billions of dollars worth of securitized products and provided client-facing research and modeling
-
Managed investment and operating teams, driving investment processes in fintech, blockchain and AI
-
CEO/CIO of a PE/Industrial fund, completing 24 investments totaling 1.13 billion RMB
-
PhD in Finance, University of Alabama
-
BS in Economics, Fudan University
Xiaohui Hao
Independent Director
-
20+ years of experience in executive leadership roles across banking, education, and international business
-
Currently serves as Executive Director & Co-CEO of Citychamp Watch & Jewellery Group and a director of its wholly owned subsidiary Bendera Bank since 2021
-
Manages various risks including management risk, operational risk and liquidity risk as a member of the Risk Management Committee of the Board of Directors
-
Previously served as Vice Chairman of the Board and non-executive director of China Chunlai Education Group from 2020-2021
-
Chairman and CEO of Yuanyin International Limited from 2018-2020, formulating overall strategy and controlling business development risks
-
Bachelor's degree in Economics and Law, Henan University
-
Two Master's degrees from Xiamen University and University of Northumbria
SCIENTIFIC ADVISOR BOARD
Nicholas A. Meanwell
PhD
-
Nicholas A. Meanwell is a distinguished medicinal chemist and drug discovery scientist and a former vice president, who spent four decades at Bristol Myers Squibb (1982–2022), where he led programs across cardiovascular, neurosciences, and virology therapeutic areas. Over the course of his career, Nick and his team advanced 33 clinical candidates, including several that reached patients as approved medicines: the HIV-1 attachment inhibitor fostemsavir (Rukobia™), the HCV NS5A inhibitor daclatasvir (Daklinza™), the HCV NS3 protease inhibitor asunaprevir (Sunvepra™), and the combination product Xymency™.
-
Nick has authored or co-authored more than 300 publications, review articles, and book chapters, delivered over 250 invited lectures worldwide, and is named as inventor or co-inventor on 145 issued U.S. patents. He served as Associate Editor of the Journal of Medicinal Chemistry from 2017 to 2023.
-
His contributions to the field have been recognized with numerous prestigious honors, including the 2015 Philip S. Portoghese Medicinal Chemistry Lectureship Award, induction into the ACS Division of Medicinal Chemistry Hall of Fame (2015), ACS "Heroes of Chemistry" Awards (2017, 2023), the 2022 Alfred Burger Award in Medicinal Chemistry, appointment as a Fellow of the American Chemical Society (2022), the 2024 Antonín Holý Memorial Award from the International Society for Antiviral Research, and the 2025 Scientific Achievement in Drug Discovery and Development Award from ASPET.
-
Nick earned his Ph.D. from the University of Sheffield and completed his postdoctoral training with Professor Carl R. Johnson at Wayne State University.
Daniel Pascheles
PhD
-
Daniel Pascheles is a pharmaceutical executive and strategic consultant with over 25 years of experience building world-class competitive intelligence organizations within global life sciences companies. He is Former CEO and Partner at Molekule Consulting LLC, a firm he joined in 2017 to advise pharmaceutical and biotechnology clients on competitive strategy and market intelligence.
-
Prior to Molekule Consulting, Dr. Pascheles spent 12 years at Merck & Co./MSD as Vice President and Head of Global Competitive Intelligence. Before that, he held senior leadership roles over 14 years at Aventis and its predecessor companies (Hoechst Marion Roussel, Marion Merrell Dow), including Global Head of CI, European Head of Sales and Marketing Administration, European Head of Strategic Planning, and General Manager Switzerland.
-
Dr. Pascheles studied Pharmacy at the Swiss Federal Institute of Technology (ETH) in Zurich and earned his Ph.D. in Pharmaceutical Technology from the same institution. He is Past-President and a current Board member of the Pharmaceutical Business Intelligence & Research Group (PBIRG), a member of the Society of Competitive Intelligence Professionals (SCIP) and the Licensing Executive Society (LES), and a Visiting Professor at Rey Juan Carlos University in Madrid. He has served on the Editorial Advisory Board of Pharmaceutical Executive magazine and is a sought-after speaker and chairman at international conferences on competitive intelligence.
Taku Kambayashi
MD, PhD
-
Taku Kambayashi is a Professor of Pathology and Laboratory Medicine at the University of Pennsylvania's Perelman School of Medicine. A physician-scientist with dual clinical and research expertise, Dr. Kambayashi is board-certified in Clinical Pathology and Transfusion Medicine and serves as Chair of the Immunology Graduate Group at Penn.
-
His laboratory investigates targetable signal transduction pathways in immune cells, with the goal of translating fundamental discoveries into therapies for autoimmune and inflammatory diseases. Key research programs include the role of TSLP-stimulated T cells in sebum secretion and adipose tissue loss (a finding with implications for obesity-related disorders), regulatory T cell homeostasis and its therapeutic manipulation in diseases such as multiple sclerosis, graft-versus-host disease, and diabetes, and diacylglycerol kinase (DGK) as a novel checkpoint target for reactivating exhausted T cells in cancer and chronic infection.
-
Dr. Kambayashi earned his B.S. in Biomedical Engineering from Johns Hopkins University and his M.D. and Ph.D. from Emory University. He completed his residency and fellowship training at the Hospital of the University of Pennsylvania. His work has been recognized with numerous awards, including the National Blood Foundation Scholar Award, the Junior Faculty Scholar Award from the American Society of Hematology, the STAT Summit Breakthrough Science Award (2022), and the Lady Barbara Colyton Award for Autoimmune Research. He is a member of the American Society of Clinical Investigation and the Henry Kunkel Society.
Selvakumar Subbian
PhD
-
Selvakumar Subbian is an Associate Professor at the Public Health Research Institute (PHRI) Center and Department of Medicine at Rutgers New Jersey Medical School, where his research is dedicated to understanding the host-pathogen interactions that determine the outcome of Mycobacterium tuberculosis (Mtb) infection — and to developing more effective therapeutic strategies against tuberculosis.
-
Dr. Subbian's laboratory has pioneered the use of rabbit models of pulmonary tuberculosis to study disease states that closely mirror human TB, including active cavitary disease, spontaneous latency, and tuberculous meningitis. His team has made significant contributions to host-directed therapy (HDT) for TB, demonstrating that phosphodiesterase-4 (PDE4) inhibition can improve antibiotic efficacy and reduce lung pathology. Ongoing work explores immunometabolism in TB, the effect of iron supplementation on bacterial persistence, and novel biomarkers of disease.
-
Dr. Subbian received his B.Sc. in Biochemistry from Bharathiar University (India) and his Ph.D. in Basic Medical Sciences from The Tamil Nadu Dr. MGR Medical University (India). He completed postdoctoral training at the University of Nebraska–Lincoln and Texas A&M Health Science Center. He is an active grant reviewer for the NIH, Wellcome Trust, and multiple international funding agencies, and serves on editorial boards of journals including PLOS ONE, Nature Scientific Reports, and Frontiers in Epidemiology. He is a Young Investigator Award recipient from the Theobald Smith Society of the American Society for Microbiology.